Decreased plasma histidine level predicts risk of relapse in patients with ulcerative colitis in remission

Tadakazu Hisamatsu, Nobukazu Ono, Akira Imaizumi, Maiko Mori, Hiroaki Suzuki, Michihide Uo, Masaki Hashimoto, Makoto Naganuma, Katsuyoshi Matsuoka, Shinta Mizuno, Mina T. Kitazume, Tomoharu Yajima, Haruhiko Ogata, Yasushi Iwao, Toshifumi Hibi, Takanori Kanai

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Ulcerative colitis (UC) is characterized by chronic intestinal inflammation. Patients with UC have repeated remission and relapse. Clinical biomarkers that can predict relapse in UC patients in remission have not been identified. To facilitate the prediction of relapse of UC, we investigated the potential of novel multivariate indexes using statistical modeling of plasma free amino acid (PFAA) concentrations. We measured fasting PFAA concentrations in 369 UC patients in clinical remission, and 355 were observed prospectively for up to 1 year. Relapse rate within 1 year was 23% (82 of 355 patients). The age-and genderadjusted hazard ratio for the lowest quartile compared with the highest quartile of plasma histidine concentration was 2.55 (95% confidence interval: 1.41-4.62; p = 0.0020 (logrank), p for trend = 0.0005). We demonstrated that plasma amino acid profiles in UC patients in clinical remission can predict the risk of relapse within 1 year. Decreased histidine level in PFAAs was associated with increased risk of relapse. Metabolomics could be promising for the establishment of a non-invasive predictive marker in inflammatory bowel disease.

Original languageEnglish
Article numbere0140716
JournalPLoS One
Volume10
Issue number10
DOIs
Publication statusPublished - 2015 Oct 16

Fingerprint

colitis
relapse
remission
Ulcerative Colitis
histidine
Histidine
Plasmas
Recurrence
Amino Acids
free amino acids
Biomarkers
Hazards
Metabolomics
inflammatory bowel disease
metabolomics
Inflammatory Bowel Diseases
fasting
confidence interval
Fasting
biomarkers

ASJC Scopus subject areas

  • Agricultural and Biological Sciences(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

Decreased plasma histidine level predicts risk of relapse in patients with ulcerative colitis in remission. / Hisamatsu, Tadakazu; Ono, Nobukazu; Imaizumi, Akira; Mori, Maiko; Suzuki, Hiroaki; Uo, Michihide; Hashimoto, Masaki; Naganuma, Makoto; Matsuoka, Katsuyoshi; Mizuno, Shinta; Kitazume, Mina T.; Yajima, Tomoharu; Ogata, Haruhiko; Iwao, Yasushi; Hibi, Toshifumi; Kanai, Takanori.

In: PLoS One, Vol. 10, No. 10, e0140716, 16.10.2015.

Research output: Contribution to journalArticle

Hisamatsu, T, Ono, N, Imaizumi, A, Mori, M, Suzuki, H, Uo, M, Hashimoto, M, Naganuma, M, Matsuoka, K, Mizuno, S, Kitazume, MT, Yajima, T, Ogata, H, Iwao, Y, Hibi, T & Kanai, T 2015, 'Decreased plasma histidine level predicts risk of relapse in patients with ulcerative colitis in remission', PLoS One, vol. 10, no. 10, e0140716. https://doi.org/10.1371/journal.pone.0140716
Hisamatsu, Tadakazu ; Ono, Nobukazu ; Imaizumi, Akira ; Mori, Maiko ; Suzuki, Hiroaki ; Uo, Michihide ; Hashimoto, Masaki ; Naganuma, Makoto ; Matsuoka, Katsuyoshi ; Mizuno, Shinta ; Kitazume, Mina T. ; Yajima, Tomoharu ; Ogata, Haruhiko ; Iwao, Yasushi ; Hibi, Toshifumi ; Kanai, Takanori. / Decreased plasma histidine level predicts risk of relapse in patients with ulcerative colitis in remission. In: PLoS One. 2015 ; Vol. 10, No. 10.
@article{ab87c60551c94e9783d4b0c10eb7987f,
title = "Decreased plasma histidine level predicts risk of relapse in patients with ulcerative colitis in remission",
abstract = "Ulcerative colitis (UC) is characterized by chronic intestinal inflammation. Patients with UC have repeated remission and relapse. Clinical biomarkers that can predict relapse in UC patients in remission have not been identified. To facilitate the prediction of relapse of UC, we investigated the potential of novel multivariate indexes using statistical modeling of plasma free amino acid (PFAA) concentrations. We measured fasting PFAA concentrations in 369 UC patients in clinical remission, and 355 were observed prospectively for up to 1 year. Relapse rate within 1 year was 23{\%} (82 of 355 patients). The age-and genderadjusted hazard ratio for the lowest quartile compared with the highest quartile of plasma histidine concentration was 2.55 (95{\%} confidence interval: 1.41-4.62; p = 0.0020 (logrank), p for trend = 0.0005). We demonstrated that plasma amino acid profiles in UC patients in clinical remission can predict the risk of relapse within 1 year. Decreased histidine level in PFAAs was associated with increased risk of relapse. Metabolomics could be promising for the establishment of a non-invasive predictive marker in inflammatory bowel disease.",
author = "Tadakazu Hisamatsu and Nobukazu Ono and Akira Imaizumi and Maiko Mori and Hiroaki Suzuki and Michihide Uo and Masaki Hashimoto and Makoto Naganuma and Katsuyoshi Matsuoka and Shinta Mizuno and Kitazume, {Mina T.} and Tomoharu Yajima and Haruhiko Ogata and Yasushi Iwao and Toshifumi Hibi and Takanori Kanai",
year = "2015",
month = "10",
day = "16",
doi = "10.1371/journal.pone.0140716",
language = "English",
volume = "10",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "10",

}

TY - JOUR

T1 - Decreased plasma histidine level predicts risk of relapse in patients with ulcerative colitis in remission

AU - Hisamatsu, Tadakazu

AU - Ono, Nobukazu

AU - Imaizumi, Akira

AU - Mori, Maiko

AU - Suzuki, Hiroaki

AU - Uo, Michihide

AU - Hashimoto, Masaki

AU - Naganuma, Makoto

AU - Matsuoka, Katsuyoshi

AU - Mizuno, Shinta

AU - Kitazume, Mina T.

AU - Yajima, Tomoharu

AU - Ogata, Haruhiko

AU - Iwao, Yasushi

AU - Hibi, Toshifumi

AU - Kanai, Takanori

PY - 2015/10/16

Y1 - 2015/10/16

N2 - Ulcerative colitis (UC) is characterized by chronic intestinal inflammation. Patients with UC have repeated remission and relapse. Clinical biomarkers that can predict relapse in UC patients in remission have not been identified. To facilitate the prediction of relapse of UC, we investigated the potential of novel multivariate indexes using statistical modeling of plasma free amino acid (PFAA) concentrations. We measured fasting PFAA concentrations in 369 UC patients in clinical remission, and 355 were observed prospectively for up to 1 year. Relapse rate within 1 year was 23% (82 of 355 patients). The age-and genderadjusted hazard ratio for the lowest quartile compared with the highest quartile of plasma histidine concentration was 2.55 (95% confidence interval: 1.41-4.62; p = 0.0020 (logrank), p for trend = 0.0005). We demonstrated that plasma amino acid profiles in UC patients in clinical remission can predict the risk of relapse within 1 year. Decreased histidine level in PFAAs was associated with increased risk of relapse. Metabolomics could be promising for the establishment of a non-invasive predictive marker in inflammatory bowel disease.

AB - Ulcerative colitis (UC) is characterized by chronic intestinal inflammation. Patients with UC have repeated remission and relapse. Clinical biomarkers that can predict relapse in UC patients in remission have not been identified. To facilitate the prediction of relapse of UC, we investigated the potential of novel multivariate indexes using statistical modeling of plasma free amino acid (PFAA) concentrations. We measured fasting PFAA concentrations in 369 UC patients in clinical remission, and 355 were observed prospectively for up to 1 year. Relapse rate within 1 year was 23% (82 of 355 patients). The age-and genderadjusted hazard ratio for the lowest quartile compared with the highest quartile of plasma histidine concentration was 2.55 (95% confidence interval: 1.41-4.62; p = 0.0020 (logrank), p for trend = 0.0005). We demonstrated that plasma amino acid profiles in UC patients in clinical remission can predict the risk of relapse within 1 year. Decreased histidine level in PFAAs was associated with increased risk of relapse. Metabolomics could be promising for the establishment of a non-invasive predictive marker in inflammatory bowel disease.

UR - http://www.scopus.com/inward/record.url?scp=84949033008&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84949033008&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0140716

DO - 10.1371/journal.pone.0140716

M3 - Article

VL - 10

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 10

M1 - e0140716

ER -